Peter Cornelius

Dr. Cornelius earned his B.A. in biology from Skidmore College and his Ph.D. in biochemistry from East Carolina University School of Medicine, where he studied the regulation of lipid and glucose metabolism by inflammatory cytokines. Following postdoctoral work at Johns Hopkins University School of Medicine, where he studied the development and function of adipose cells, he joined the Department of Cardiovascular & Metabolic Diseases at Pfizer. During his career at Pfizer (1995-2011), he initiated numerous projects and led successful teams that identified clinical candidates targeting diverse pathways impacting dyslipidemia, obesity and type 2 diabetes.

Prior to joining SynDevRx in 2015, Dr. Cornelius held senior positions at two startup biotech companies, SystaMedic and Wellomics, where he made significant contributions to each company’s pipeline. Throughout his career, he has published extensively in peer-reviewed journals and presented frequently at both national and international conferences.